Peter Wirth

Track

Insider profile

Currently holds positions in Genzyme Corp and Syros Pharmaceuticals Inc

Performance

Overall performance
0.5
Performance over holding periods
0.5
30 days 90 days 120 days
Average return -26% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Executive Vice President - Legal and Corporate Development, Secretary Genzyme Corp May 22, 2008 -
Independent Chairman of the Board Syros Pharmaceuticals Inc Jan. 27, 2017 -
Peter Wirth's trades of Syros Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-11 2025-03-11
PrS Proposed sale
72,169
421.83
US$52,528 		72,169 421.83 US$52,528
2022-12-09 2022-12-08
US Zai Lab Ltd (9688)
S Sale
67,926 +47.9%
489.85
US$3,349,824 		67,926 +47.9% 489.85 US$3,349,824
2022-12-09 2022-12-08
US Zai Lab Ltd (9688)
S Sale
44,828 -35.3%
280.64
US$469,634 		44,828 -35.3% 280.64 US$469,634
2021-12-08 2021-12-08
US Zai Lab Ltd (9688)
B Purchase
4,000 +1.2%
71.36
US$285,440 		4,000 +1.2% 71.36 US$285,440
2020-06-24 2020-06-23
S Sale
14,026
0.00
US$0 		14,026 0.00 US$0
2020-06-24 2020-06-23
S Sale
10,240
0.00
US$0 		10,240 0.00 US$0
2020-06-24 2020-06-23
S Sale
9,847
0.00
US$0 		9,847 0.00 US$0
2020-06-24 2020-06-23
S Sale
18,585
0.00
US$0 		18,585 0.00 US$0
2020-06-24 2020-06-23
S Sale
25,756
0.00
US$0 		25,756 0.00 US$0
2020-06-24 2020-06-23
B Purchase
63,299
0.00
US$0 		63,299 0.00 US$0